Drug Profile
STABX 909
Alternative Names: STA-BX909Latest Information Update: 07 Nov 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Toyo Hakka
- Class Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 07 Nov 2002 No development reported - Preclinical for Glioma in Japan (unspecified route)
- 28 Feb 2000 Preclinical development for Glioma in Japan (Unknown route)